HVB MINI FUTURE BEAR - ROCHE GS Share Price

Certificat

DE000HB7JB58

Market Closed - BOERSE MUENCHEN 01:15:25 01/06/2024 am IST
9.08 EUR -4.42% Intraday chart for HVB MINI FUTURE BEAR - ROCHE GS
1 month-12.10%
3 months-13.77%
Date Price Change
31/24/31 9.08 -4.42%
30/24/30 9.5 +2.81%
29/24/29 9.24 -0.86%
28/24/28 9.32 +1.41%
27/24/27 9.19 +0.33%

Real-time BOERSE MUENCHEN

Last update May 01, 2024 at 01:15 am IST

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer UniCredit UniCredit
WKN HB7JB5
ISINDE000HB7JB58
Date issued 15/06/2022
Strike 321.2 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 5.21
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 11.68
Lowest since issue 1.92

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus